- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Dr. Paul M. Steed to Head IND Enabling Studies For Next Generation Targeted Cancer Drug
NanoVector, Inc. announced today that Paul M. Steed, Ph.D. has joined the company as its Vice President of Research and Development. Dr. Steed has 16 years of experience in pharmaceutical R & D, including 10 at Ciba/Novartis and 6 in the biotech industry. He has a thorough understanding of all aspects of pharmaceutical R&D, primarily in the areas of oncology and inflammation/immunology and has numerous high-impact publications. Most recently Dr. Steed served as head of biology for Serenex, which was acquired in April of 2008 by Pfizer, Inc; primarily for its oncology products in clinical and pre-clinical development. At Serenex Dr. Steed managed all aspects of biological research and preclinical biology and helped guide the lead cancer drug SNX-5422 through early development. His background spans small molecules and biologics, a unique combination essential for efficient progress of the NanoVector technology.
"We are delighted to have the opportunity to add someone of Dr. Steed's background to our senior management team," said Albert Bender, Ph.D. CEO. "Leveraging his extensive oncology development experience and leadership, Dr. Steed will accelerate our lead drug time to IND." Dr. Steed added, "I am excited to lead the effort to bring the NanoVector technology to fruition because it clearly can be a breakaway advancement in the treatment of cancer and potentially many other diseases."
About NanoVector, Inc.
NanoVector Inc. is commercializing the first biologic-based nanoparticle drug delivery system for the $48B/yr global cancer therapeutics market. Our breakaway technology overcomes all of the hurdles that have impeded chemistry-based nanocarrier systems and is capable of delivering selective targeting of tumors along with the precise intracellular delivery of anti-cancer agents for improved efficacy and fewer unpleasant side effects. The NanoVector technology is based upon a ubiquitous plant virus that has evolved for millions of years to have these ideal drug delivery characteristics, along with the ability to be exposed to mammals (including humans) in a completely benign fashion. To limit uptake to diseased cells, NanoVector has intelligently engineered the surface of the nanocarrier with targeting technology that specifically and exclusively targets tumor cells and the cell components relevant for the treatment/cargo. This technology transcends the long-standing drug paradigm for treating diseases.
For more information, please click here
Albert Bender, Ph.D., CEO
Copyright © Business Wire 2009If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Springer and Tsinghua University Press present the second Nano Research Award: Paul Alivisatos of the University of California Berkeley receives the honor for outstanding contributions in nanoscience July 30th, 2015
European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015
BESSTECH Names Doug Grose as Chief Technology Officer: Former GLOBALFOUNDRIES CEO to drive technology roadmap and strategic partnerships for emerging lithium-ion battery component company July 14th, 2015
A cool way to form 2-D conducting polymers using ice: POSTECH scientists develop breakthrough technique to easily optimize electrical properties of Polyaniline nanosheets to an unprecedented level in an environmental-friendly and inexpensive way July 7th, 2015